AUSTIN, TX – Tekton Research, a clinical research company focusing on clinical trials for pharmaceuticals and device companies, is excited to announce the appointment of Russell Smith as their new Chief Operating Officer (COO). With over 20 years of clinical research experience, Russell brings a depth of knowledge in the leadership and management sphere.
“I am both thrilled and humbled to join the organization in this next phase of strategic growth,” said Russell. “Tekton has an enviable track record of success in research.”
As COO, Russell will oversee operations and support revenue growth and therapeutic expansion. One of his primary focus areas will be the expansion of Tekton’s capabilities, including site and investigator growth. He will also work closely with the executive team to ensure Tekton continues its commitment to providing high-quality services for clients in the clinical research industry.
Kip McKenzie, Tekton Research Chief Executive Officer, is delighted to welcome Russell to the team. “I am excited to add Russell to our strategically developed leadership team. He will be instrumental in our growth over the next few years,” said Kip.
With a Bachelor of Science (BS) in Management and a Master of Business Administration (MBA) from Southern New Hampshire University, Russell has successfully managed numerous high-profile clinical research positions throughout his career.
Previously, Russell served as Vice President and Head of Frenova Renal Research, a global site network owned by Fresenius Medical Care. During his tenure at Frenova, he had leadership and P&L responsibility for the company’s multi-tiered site network inclusive of 550 Principal Investigators and 350 research sites. He also served on the Fresenius Global Medical Office (GMO) Leadership Team and Emerging Businesses Leadership Team, in addition to previously being Head of Business Operations, Sales, and Marketing.
For more information or to request a meeting, contact [email protected].
